Gelernter Joel, Panhuysen Carolien, Wilcox Marsha, Hesselbrock Victor, Rounsaville Bruce, Poling James, Weiss Roger, Sonne Susan, Zhao Hongyu, Farrer Lindsay, Kranzler Henry R
Division of Human Genetics, Department of Psychiatry, Yale University School of Medicine, New Haven; VA Connecticut Healthcare Center, West Haven.
Genetics Program, Department of Medicine, Boston University School of Medicine, Boston; Department of Biostatistics, School of Public Health, Boston University School of Medicine, Boston.
Am J Hum Genet. 2006 May;78(5):759-769. doi: 10.1086/503631. Epub 2006 Mar 16.
Risk of opioid dependence is genetically influenced. We recruited a sample of 393 small nuclear families (including 250 full-sib and 46 half-sib pairs), each with at least one individual with opioid dependence. Subjects underwent a detailed evaluation of substance dependence-related traits. As planned a priori to reduce heterogeneity, we used cluster analytic methods to identify opioid dependence-related symptom clusters, which were shown to be heritable. We then completed a genomewide linkage scan (with 409 markers) for the opioid-dependence diagnosis and for the two cluster-defined phenotypes represented by >250 families: the heavy-opioid-use cluster and the non-opioid-use cluster. Further exploratory analyses were completed for the other cluster-defined phenotypes. The statistically strongest results were seen with the cluster-defined traits. For the heavy-opioid-use cluster, we observed a LOD score of 3.06 on chromosome 17 (empirical pointwise P = .0002) for European American (EA) and African American (AA) subjects combined, and, for the non-opioid-use cluster, we observed a LOD score of 3.46 elsewhere on chromosome 17 (empirical pointwise P = .00002, uncorrected for multiple traits studied) for EA subjects only. We also identified a possible linkage (LOD score 2.43) of opioid dependence with chromosome 2 markers for the AA subjects. These results are an initial step in identifying genes for opioid dependence on the basis of a genomewide investigation (i.e., a study not conditioned on prior physiological candidate-gene hypotheses).
阿片类药物依赖风险受遗传影响。我们招募了393个小核家庭样本(包括250个全同胞对和46个半同胞对),每个家庭至少有一名阿片类药物依赖个体。受试者接受了物质依赖相关特征的详细评估。为了如先验计划那样减少异质性,我们使用聚类分析方法来识别阿片类药物依赖相关症状群,结果显示这些症状群具有遗传性。然后,我们针对阿片类药物依赖诊断以及由超过250个家庭代表的两种聚类定义表型(重度阿片类药物使用群和非阿片类药物使用群)完成了全基因组连锁扫描(使用409个标记)。对其他聚类定义表型进行了进一步的探索性分析。聚类定义特征的统计学结果最为显著。对于重度阿片类药物使用群,我们在17号染色体上观察到欧美裔(EA)和非裔美国人(AA)受试者合并后的LOD得分为3.06(经验逐点P = 0.0002),对于非阿片类药物使用群,仅在EA受试者中,我们在17号染色体其他位置观察到LOD得分为3.46(经验逐点P = 0.00002,未针对所研究的多个性状进行校正)。我们还在AA受试者中发现阿片类药物依赖与2号染色体标记可能存在连锁(LOD得分2.43)。这些结果是基于全基因组研究(即一项不依赖先前生理候选基因假说的研究)来识别阿片类药物依赖相关基因的初步步骤。